Drugs / SHR-4610
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07231211 | Nov 2025 → Oct 2026 expected | cancer | Shanghai Shengdi Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-4610 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07231211 ↗ |